Isolated limb infusion for melanoma

Simple item page
dc.contributor.authorBeasley, G.
dc.contributor.authorMiura, J.
dc.contributor.authorZager, J.
dc.contributor.authortyler, D.
dc.contributor.authorThompson, J.
dc.contributor.authorHidde, K.
dc.contributor.authorKroon, H.M.
dc.contributor.editorThompson, J.
dc.contributor.editorGershenwald, J.
dc.contributor.editorAtkins, M.
dc.contributor.editorKirkwood, J.
dc.contributor.editorMcArthur, G.
dc.contributor.editorSober, A.
dc.contributor.editorHalpern, A.
dc.contributor.editorGarbe, C.
dc.contributor.editorScoyler, R.
dc.date.issued2020
dc.description.abstractIsolated limb infusion (ILI) using melphalan and dactinomycin (actinomycin D) was developed as a simplified and minimally invasive alternative to the traditional, more invasive, and elaborative isolated limb perfusion (ILP) to treat unresectable metastatic melanoma confined to the limb. An increasing number of centers around the world have reported their results using the procedure. Reports from different centers have shown that the procedure is safe, with mild-to-moderate regional toxicity, and results in satisfactory response rates. When comparing ILI and ILP, it must be borne in mind that ILI is often performed in significantly older patients and in patients with higher stages of disease, which decreases the likelihood of a favorable response. Even in this era of effective systemic therapies for metastatic melanoma, ILI is still worthwhile and a relatively straightforward, single-treatment option to treat locally recurrent or in-transit metastatic melanoma involving a limb. Due to its minimally invasive nature, ILI is an ideal platform to test new drugs and drug combinations. Potential exists to further improve ILI response rates when combined with novel therapies.
dc.description.statementofresponsibilityGeorgia Marie Beasley, John T. Miura, Jonathan S. Zager, Douglas S. Tyler, John F. Thompson, and Hidde M. Kroon
dc.identifier.citationCutaneous Melanoma, 2020 / Thompson, J., Gershenwald, J., Atkins, M., Kirkwood, J., McArthur, G., Sober, A., Halpern, A., Garbe, C., Scoyler, R. (ed./s), vol.1, Ch.30, pp.827-850
dc.identifier.doi10.1007/978-3-030-05070-2_27
dc.identifier.isbn3030050688
dc.identifier.isbn9783030050689
dc.identifier.orcidKroon, H.M. [0000-0002-8923-7527]
dc.identifier.urihttps://hdl.handle.net/2440/140317
dc.language.isoen
dc.publisherSpringer
dc.publisher.placeCham, Switzerland
dc.rights© Springer Nature Switzerland AG 2020
dc.source.urihttps://link.springer.com/referenceworkentry/10.1007/978-3-030-05070-2_27
dc.subjectMedical
dc.subjectIsolated limb infusion (ILI)
dc.titleIsolated limb infusion for melanoma
dc.typeBook chapter
pubs.publication-statusPublished

Files

Collections

Surgery publications